Cervomed Inc. revenue
Cervomed Inc.'s revenue was $4.0m in fiscal 2025, down 58.9% on the year before. Since fiscal 2010 ($40,189) it has grown at a compound 93.0% a year. Over the last twelve months it was $331,295.
Revenue history
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 570 | 375 | 72 | 0 | 7,145 | 9,738 | 4,007 | 331 |
| Growth on the year before | — | +>999% | −34.3% | −80.9% | −100.0% | — | +36.3% | −58.9% | — |
| Gross profit | −170 | −1,738 | 139 | 72 | — | — | — | — | — |
| Gross margin | — | — | 37.0% | 100.0% | — | — | — | — | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Cervomed Inc. | $331,295 | -95.7% | -52.7% |
| Cardiff Oncology, Inc. | $508,000 | -7.0% | 7.2% |
| Clene Inc. | $197,000 | -31.1% | -36.9% |
| Celldex Therapeutics, Inc. | $158,000 | -97.3% | -63.5% |
| Medicinova Inc | $920,481 | 875.7% | — |
| Shattuck Labs, Inc. | $1.0m | -66.6% | 5.2% |
Compare with peers
- Cardiff Oncology, Inc. revenue
- Clene Inc. revenue
- Celldex Therapeutics, Inc. revenue
- Medicinova Inc revenue
- Shattuck Labs, Inc. revenue
Head to head: CRDF vs CRVOCLNN vs CRVOCLDX vs CRVO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies